Alnylam Pharmaceuticals Inc (ALNY)
143.39
+6.02 +4.38%
NASDAQ
Mar 5, 20:00
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 492.85M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -7.454 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -858.28M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 85.92% |
| Profit Margin (Quarterly) | -148.9% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 16.78B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 33.45 |
| PE Ratio | -- |
| Price to Book Value | 16.51 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.1882 |
| Free Cash Flow (Quarterly) | -144.81M |
| Return on Equity | Upgrade |
View All ALNY News
News
-
WireHeadlineTime (ET)
-
Yahoo03/02 07:00
-
MT Newswires03/01 10:19
-
Yahoo02/22 16:00
-
MT Newswires02/22 08:43
-
Yahoo02/18 16:00
-
MT Newswires02/12 11:43
-
Yahoo02/12 10:06
-
MT Newswires02/12 09:44
-
MT Newswires02/12 09:18
-
SA Breaking News02/12 09:18
-
MT Newswires02/12 09:11
-
MT Newswires02/12 09:10
-
MT Newswires02/12 09:09
-
MT Newswires02/11 15:50
-
Yahoo02/11 13:30
-
SA Breaking News02/11 10:32
-
Yahoo02/11 09:55
-
Yahoo02/11 09:35
-
MT Newswires02/11 08:28
-
MT Newswires02/11 08:01
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 05/06/2021 | Earnings | Alnylam Pharmaceuticals Inc First Quarter Earnings Results for 2021 |
| 05/06/2021 | Misc | Alnylam Pharmaceuticals Inc First Quarter Earnings Conference Call for 2021 |
| 02/11/2021 | Earnings | Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Result for 2020 |
| 02/11/2021 08:30 EST | Misc | Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2020 |
| 02/11/2021 | Misc | Alnylam Pharmaceuticals Inc Annual Report for 2020 |
| 11/05/2020 | Earnings | Alnylam Pharmaceuticals Inc Third Quarter Earnings Result for 2020 |
| 11/05/2020 08:30 EST | Misc | Alnylam Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2020 |
| 08/06/2020 | Earnings | Alnylam Pharmaceuticals Inc Second Quarter Earnings Result for 2020 |
| 08/06/2020 08:30 EDT | Misc | Alnylam Pharmaceuticals Inc Second Quarter Earnings Conference Call for 2020 |
| 05/06/2020 12:00 EDT | Misc | Alnylam Pharmaceuticals Inc Annual General Meeting for 2019 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.alnylam.com
- Investor Relations URL: http://investors.alnylam.com/index.cfm
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: May. 06, 2021
- Last Earnings Release: Feb. 11, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Alnylam Pharmaceuticals Inc is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 143.39 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| FIJYX | Fidelity Advisor® Biotechnology Z | 5.22% |
| FBT | First Trust NYSE Arca Biotech ETF | 3.12% |
| BBH | VanEck Vectors Biotech ETF | 3.07% |
| FBIOX | Fidelity® Select Biotechnology | 2.44% |
| VGHCX | Vanguard Health Care Inv | 2.16% |
| HQL | Tekla Life Sciences Investors | 2.06% |
| IBB | iShares Nasdaq Biotechnology ETF | 1.39% |
| FSPHX | Fidelity® Select Health Care | 1.33% |
| HQH | Tekla Healthcare Investors | 1.22% |
| XBI | SPDR® S&P Biotech ETF | 1.00% |
| FGCKX | Fidelity® Growth Company K | 0.84% |
| FCGSX | Fidelity® Series Growth Company | 0.80% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ALNY Tweets Stocktwits
Advertisement
